Meurer M, Wozel G
Klinik und Poliklinik für Dermatologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden.
Hautarzt. 2003 May;54(5):424-31. doi: 10.1007/s00105-003-0526-1. Epub 2003 Apr 4.
In about 60% of cases, atopic eczema can persist in adulthood with distinctive clinical features and disease course. The introduction of the topical calcineurin inhibitors pimecrolimus 1% cream and tacrolimus 0.03 and 0.1% ointment clearly improves the long-term management of atopic eczema in adult patients; this has been shown in several large clinical studies and is confirmed by the growing practical experience with these substances. Topical calcineurin inhibitors are, even when applied for weeks and months, safe, well tolerated and efficient; they have a rapid and positive effect on pruritus and the potential--as shown in clinical studies with pimecrolimus 1% cream--to reduce the number of eczema flares, to significantly prolong the time to a first flare and to reduce or even eliminate the need for topical corticosteroids.
在约60%的病例中，特应性皮炎可在成年期持续存在，具有独特的临床特征和病程。外用钙调神经磷酸酶抑制剂1%吡美莫司乳膏以及0.03%和0.1%他克莫司软膏的引入，显著改善了成年特应性皮炎患者的长期治疗；这已在多项大型临床研究中得到证实，且随着对这些药物实际应用经验的增加而得到进一步确认。外用钙调神经磷酸酶抑制剂即使连续使用数周和数月，也是安全、耐受性良好且有效的；它们对瘙痒具有快速且积极的作用，并且——如1%吡美莫司乳膏的临床研究所示——有可能减少湿疹发作次数、显著延长首次发作时间，并减少甚至消除对外用糖皮质激素的需求。
